Meronem (Meropenem Anhydrous)

Meropenem binds to penicillin‑binding proteins on bacterial cell walls, blocking the final steps of peptidoglycan cross‑linking. This weakens the cell wall, causing osmotic rupture and bacterial death, providing broad‑spectrum activity against many Gram‑negative, Gram‑positive and anaerobic organisms.

The dosage of Meronem is individualized by the prescribing clinician based on infection severity, patient weight, renal function and local guidelines. Only a qualified healthcare professional should determine the appropriate regimen.

Safety data for meropenem in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Meronem, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Meronem (meropenem) shares the carbapenem class’s broad‑spectrum activity but offers enhanced stability against many β‑lactamases, providing reliable coverage for resistant Gram‑negative pathogens. Compared with imipenem‑cilastatin, meropenem does not require co‑administration of a renal dehydropeptidase inhibitor, simplifying dosing.

Meronem should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept under the same temperature conditions.

Meronem is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central line, typically over a 15‑30 minute infusion period, following the dose prescribed by the clinician.

Serious adverse events include seizures, especially in patients with pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and acute renal impairment. Prompt recognition and discontinuation are essential if these occur.

Patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation should avoid Meronem. Caution is also advised for individuals with a history of seizures, severe renal dysfunction, or uncontrolled epilepsy, where alternative therapy may be preferred.